82 related articles for article (PubMed ID: 11006134)
1. Farnesyl transferase inhibitors: current developments and future perspectives.
Eskens FA; Stoter G; Verweij J
Cancer Treat Rev; 2000 Oct; 26(5):319-32. PubMed ID: 11006134
[TBL] [Abstract][Full Text] [Related]
2. [Farnesyl transferase inhibitors: one target may be found in another].
Mazières J; Pradines A; Favre G
Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
Girgert R; Hohnecker A; Wittrock J; Schweizer P
Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
[TBL] [Abstract][Full Text] [Related]
6. Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus.
Dong DL; Liu R; Sherlock R; Wigler MH; Nestler HP
Chem Biol; 1999 Mar; 6(3):133-41. PubMed ID: 10074468
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl-derived inhibitors of ras farnesyl transferase.
Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
9. Current progress on farnesyl protein transferase inhibitors.
Singh SB; Lingham RB
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):225-44. PubMed ID: 11926129
[TBL] [Abstract][Full Text] [Related]
10. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
Wittrock J; Schweizer P; Girgert R
Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
Kohl NE; Koblan KS; Omer CA; Oliff A; Gibbs JB
Methods Mol Biol; 1998; 84():283-91. PubMed ID: 9666457
[TBL] [Abstract][Full Text] [Related]
12. Mob-1, a Ras target gene, is overexpressed in colorectal cancer.
Zhang R; Zhang H; Zhu W; Pardee AB; Coffey RJ; Liang P
Oncogene; 1997 Apr; 14(13):1607-10. PubMed ID: 9129152
[TBL] [Abstract][Full Text] [Related]
13. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
14. v-Src transformation is mediated through farnesylated proteins.
Teng S; Sun J; Irby R; Hamilton AD; Sebti S; Yeatman TJ
J Surg Res; 2001 Aug; 99(2):343-6. PubMed ID: 11469908
[TBL] [Abstract][Full Text] [Related]
15. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
16. Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
Njoroge FG; Vibulbhan B; Pinto P; Strickland C; Kirschmeier P; Bishop WR; Girijavallabhan V
Bioorg Med Chem Lett; 2004 Dec; 14(23):5877-80. PubMed ID: 15501060
[TBL] [Abstract][Full Text] [Related]
17. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.
Johnston SR
Lancet Oncol; 2001 Jan; 2(1):18-26. PubMed ID: 11905614
[TBL] [Abstract][Full Text] [Related]
18. [Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
Eskens FA; de Jonge MJ; Verweij J
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2208-13. PubMed ID: 11757242
[TBL] [Abstract][Full Text] [Related]
19. Using inhibitors of prenylation to block localization and transforming activity.
Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective farnesyl transferase inhibitors.
Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
